Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients

• Published in: Thrombosis and haemostasis Vol. 102; no. 2; p. 268
• Main Authors: Palareti, Gualtiero, Cosmi, Benilde
• Format: Journal Article
• Language: English
• Published: Germany 01.08.2009
• Subjects: Age Factors; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Aryl Hydrocarbon Hydroxylases - genetics; Cytochrome P-450 CYP2C9; Drug Interactions; Female; Genetic Predisposition to Disease; Hemorrhage - blood; Hemorrhage - chemically induced; Hemorrhage - genetics; Hemorrhage - prevention & control; Humans; International Normalized Ratio; Male; Mixed Function Oxygenases - genetics; Pharmacogenetics; Risk Factors; Time Factors; Vitamin K - antagonists & inhibitors; Vitamin K Epoxide Reductases; Warfarin - administration & dosage; Warfarin - adverse effects
• ISSN: 0340-6245
• DOI: 10.1160/TH08-11-0730

Anticoagulation with vitamin K antagonists (VKAs) has been shown to be effective in the prevention and treatment of thrombotic complications in various clinical settings, including atrial fibrillation (AF), venous thromboembolism (VTE), acute coronary syndromes and after invasive cardiac procedures....